The incidence of acute myelogenous leukemia (AML) increases with aging. Due to the low complete remission rate and high treatment-related mortality and the poor prognosis, there is lack of unified and effective therapeutic strategies for elderly patients with AML. In this paper, we reviewed the current situation on treatment of AML in the elderly, including the roles of conventional chemotherapy, allogeneic stem cell transplantation and some novel targeted agents.